Introduction {#s1}
============

Protein Phosphatase 2A (PP2A) is a major class of serine/threonine phosphatase that is composed of a catalytic (C), scaffold (A) and regulatory (B) subunit. Substrate specificity is mediated by the regulatory B subunits, which can be subdivided into four structurally distinct families: B (B55), B' (B56), B' (PR72) and B'' (Striatin) ([@bib36]).

In humans, the B subunits are encoded by a total of 15 separate genes which give rise to at least 26 different transcripts and splice variants; therefore, each of the four B subfamilies are composed of multiple different isoforms ([@bib36]). Although these isoforms are thought to have evolved to enhance PP2A specificity, there is still no direct evidence that isoforms of the same subfamily can regulate specific pathways or processes. Perhaps the best indirect evidence that they can comes from the observation that B56 isoforms localise differently during mitosis ([@bib2]; [@bib27]). However, even in these cases, it is still unclear how this differential localisation is achieved or why it is needed.

We addressed this problem by focussing on prometaphase, a stage in mitosis when PP2A activity is essential to regulate sister chromatid cohesion ([@bib16]; [@bib32]; [@bib40]), kinetochore-microtubule attachments ([@bib8]; [@bib17]; [@bib38]; [@bib49]) and the spindle assembly checkpoint ([@bib7]; [@bib27]). Crucially, all of these mitotic functions are controlled by PP2A-B56 complexes that localise to either the centromere or the kinetochore.

The kinetochore is a multiprotein complex that assembles on centromeres to allow their physical attachment to microtubules. This attachment process is stochastic and error-prone, and therefore it is safeguarded by two key regulatory processes: the spindle assembly checkpoint (SAC) and kinetochore-microtubule error-correction. The SAC preserves the mitotic state until all kinetochores have been correctly attached to microtubules, whereas the error-correction machinery removes any faulty microtubule attachments that may form. The kinase Aurora B is critical for both processes because it phosphorylates the kinetochore-microtubule interface to destabilise incorrectly attached microtubules and it reinforces the SAC, in part by antagonising Knl1-PP1, a kinetochore phosphatase complex needed for SAC silencing ([@bib35]). These two principal functions of Aurora B are antagonised by PP2A-B56, which localises to the Knl1 complex at the outer kinetochore by binding directly to BubR1 ([@bib8]; [@bib17]; [@bib38]; [@bib49]). This interaction is mediated by the B56 subunit, which interacts with a phosphorylated LxxIxE motif within the kinetochore attachment regulatory domain (KARD) of BubR1 ([@bib44]; [@bib45]).

As well as localising to the outer kinetochore, PP2A-B56 also localises to the centromere by binding to shugoshin 1 and 2 (Sgo1/Sgo2) ([@bib16]; [@bib32]; [@bib33]; [@bib40]; [@bib41]; [@bib48]). The crystal structure of Sgo1 bound to PP2A-B56 has been solved to reveal a bipartite interaction between Sgo1 and the regulatory and catalytic subunits of the PP2A-B56 complex ([@bib48]). This interaction is thought to allow centromere-localised PP2A-B56 to counteract various kinases, such as Aurora B, which remove cohesin rings from chromosome arms during early mitosis in higher eukaryotes ([@bib23]). The result is that cohesin is specifically preserved at the centromere where it is needed to resist the pulling forces exerted by microtubules. As well as preserving cohesion at the centromere, PP2A-B56 is also thought to balance the net level of Aurora B activation in this region ([@bib26]).

In human cells, B56 isoforms are encoded by five separate genes (B56α, β, γ, δ and ε). The interaction interfaces involved in BubR1 and Sgo1 binding are extremely well conserved between all of these B56 isoforms ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). This explains why BubR1 and Sgo1 appear to display no specificity for individual B56 isoforms ([@bib16]; [@bib17]; [@bib32]; [@bib49]; [@bib48]), and why these isoforms have been proposed to function redundantly at kinetochores during mitosis ([@bib8]).

However, one crucial observation throws doubt over this issue of redundancy: individual B56 isoforms localise differentially to either the kinetochore or centromere in human cells ([@bib26]; [@bib27]). It is therefore not easy to reconcile this differential localisation with the evidence presented above, which implies that the centromere and kinetochore receptors for B56 do not display any selectivity for individual isoforms. This caused us to readdress the question of redundancy and isoform specificity in human cells.

Results {#s2}
=======

PP2A-B56 isoforms have specific roles at the centromere and kinetochore during mitosis {#s2-1}
--------------------------------------------------------------------------------------

PP2A-B56 isoform localisation to the centromere and kinetochore was visualised in nocodazole-arrested HeLa Flp-in cells expressing YFP-tagged B56 subunits. This revealed that while some B56 isoforms localise predominantly to the sister kinetochore pairs marked by Cenp-C (B56γ and δ), others localise mainly to the centromere defined by Sgo2 (B56α and ε), and one isoform displayed a mixed localisation pattern (B56β) ([Figure 1a,b](#fig1){ref-type="fig"}). B56 isoforms have been proposed to act redundantly at the kinetochore in human cells ([@bib8]), therefore we readdressed this question in light of their differential localisation. B56α and B56γ were chosen as representative members of the centromere and kinetochore-localised pools, respectively, since these isoforms could both be readily detected by western blot analysis of HeLa cell lysates ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Furthermore, both genes were endogenously tagged using CRISPR/Cas9-mediated homologous recombination to demonstrate consistent expression and differential localisation to either the centromere or kinetochore ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). All B56 isoforms were then depleted, except for either B56α or B56γ ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), to determine whether these endogenous isoforms could support centromere and kinetochore functions.

![A subset of PP2A-B56 complexes control spindle assembly checkpoint silencing and chromosome alignment.\
(**A** and **B**) Representative images (**A**) and line plots (**B**) of nocodazole-arrested Flp-in HeLa cells expressing YFP-B56 (B56α, B56β, B56γ1, B56γ3, B56δ and B56ε). For line plots, five kinetochore pairs were analysed per cell, for a total of 10 cells per experiment. Graphs represent the mean intensities (±SD) from 3 independent experiments. Intensity is normalized to the maximum signal in each channel in each experiment. (**C--G**) Flp-in HeLa cells treated with siRNA against B56pool, all B56 isoforms except B56α, or all B56 isoforms except B56γ, were analysed for sister chromatid cohesion, SAC strength, Knl1-MELT dephosphorylation and chromosomal alignment. (**C**) Quantification of percentage of chromosome spreads that contain at least one split centromere. Graph represents mean data (+SD) from 3 independent experiments with 50 metaphase spreads quantified per condition per experiment. (**D**) Time-lapse analysis of cells entering mitosis in the presence of nocodazole and 2.5 µM AZ-3146. The graph represents the cumulative data from 50 cells, which is representative of 3 independent experiments. Representative images (**E**) and quantification (**F**) of relative kinetochore intensities of Knl1-pMELT in cells arrested in prometaphase with nocodazole and treated with MG132 for 30 min, followed by 2.5 µM AZ-3146 for the indicated amount of time. 10 cells were quantified per experiment and the graph displays the mean (+SD) of 3 independent experiments. The individual data points for each experiment can be found in the source data. (**G**) Quantification of chromosome misalignment in cells arrested in metaphase with MG-132. At least 100 cells were scored per condition per experiment and graph represents the mean (-SD) of 3 independent experiments. Misalignments were score as mild (1 to 2 misaligned chromosomes), intermediate (3 to 5 misaligned chromosomes), and severe (\>5 misaligned chromosomes). Asterisks indicate significance ([Figure 1c](#fig1){ref-type="fig"}: Welch's t -test, unpaired, [Figure 1f](#fig1){ref-type="fig"}: Mann-Whitney test); ns p\>0.05, \*p≤0.05, \*\*p≤0.01, \*\*\*\*p≤0.0001. Scale bars, 5µm.](elife-42619-fig1){#fig1}

Centromeric PP2A-B56 is important for maintaining sister chromatid cohesion during mitosis in human cells ([@bib23]). In agreement with our differential localisation data, only the centromere-localised B56α was able to support proper centromeric cohesion ([Figure 1c](#fig1){ref-type="fig"}). In fact, we observed no difference in the extent of sister chromatid splitting when comparing loss of all B56 isoforms to a situation when only B56γ is retained ([Figure 1c](#fig1){ref-type="fig"}). Therefore, sister chromatid cohesion can be supported by a B56 isoform that localises primarily to the centromere (B56α), but not by one that localises to the kinetochore (B56γ).

To examine which B56 isoforms can support kinetochore functions, we first focussed on SAC signalling. The SAC is activated at kinetochores by the phosphorylation of 'MELT' repeats on Knl1 by the kinase Mps1 ([@bib22]; [@bib37]; [@bib51]). These phosphorylated repeats recruit a variety of SAC proteins to the kinetochore, which are then assembled into an inhibitory complex that is released into the cytosol to prevent mitotic exit ([@bib35]). PP2A-B56 antagonises this process, as evidenced by the fact that removal of B56 from kinetochores prevents Knl1-MELT dephosphorylation and delays mitotic exit following Mps1 inhibition in nocodazole ([@bib7]; [@bib27]). Therefore, we sought to address whether these effects were dependent on specific B56 isoforms.

As expected, simultaneous depletion of all B56 isoforms enhanced basal Knl1-MELT phosphorylation in nocodazole, delayed MELT dephosphorylation upon Mps1 inhibition with AZ-3146 ([@bib11]), and prevented mitotic exit under identical conditions ([Figure 1d--f](#fig1){ref-type="fig"}). Importantly, these effects were all rescued when endogenous B56γ was preserved, but not if only B56α remained ([Figure 1d--f](#fig1){ref-type="fig"}). Kinetochore PP2A-B56 also has well-established roles in chromosome alignment where it is needed to antagonise Aurora B and allow initial kinetochore-microtubule attachment to form ([@bib8]; [@bib17]; [@bib38]; [@bib49]). Knockdown of all B56 isoforms produced severe defects in chromosome alignment, as expected, and these effects could be rescued by preserving B56γ, but not B56α ([Figure 1g](#fig1){ref-type="fig"}). In summary, only the kinetochore-localised B56γ, and not the centromeric B56α, can support SAC silencing and chromosome alignment in human cells.

Overexpression of GFP-B56α has previously been shown to rescue kinetochore-microtubule attachment defects following the depletion of all PP2A-B56 isoforms in human cells ([@bib8]). To understand the discrepancy with our data, we performed the same assays as previously, but this time expressing siRNA-resistant YFP-B56α or YFP-B56γ to rescue the knockdown of all endogenous B56 isoforms. Under these conditions, both exogenous B56 isoforms were able to rescue MELT dephosphorylation, SAC silencing and chromosome alignment ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). The ability of exogenous YFP-B56α to support kinetochore functions can be explained by the fact that it is highly overexpressed, which leads to elevated centromere and kinetochore levels in comparison to the endogenous YFP-B56α situation ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). We therefore conclude B56α acts primarily at the centromere, but it can still function at the kinetochore when overexpressed. In summary, under endogenous conditions, PP2A-B56 isoforms localise differentially to the centromere or kinetochore where they carry out specific roles in sister chromatid cohesion, SAC silencing and chromosomal alignment.

We next sought to determine the molecular explanation for differential B56 isoform localisation. This was difficult to reconcile with existing structural data mapping the interaction between PP2A-B56 and the reported kinetochore and centromere receptors - BubR1 and Sgo1 -- since these demonstrate that the key interacting residues are well conserved between all B56 isoforms ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) ([@bib44]; [@bib45]; [@bib48]). Furthermore, biochemical studies could not detect a difference in association between different B56 isoforms and either BubR1 or Sgo1 ([@bib16]; [@bib17]; [@bib49]). Therefore, we decided to first test whether BubR1 or Sgo1 were the only receptors for B56 at the kinetochore and centromere.

Sgo2 provides specificity for centromeric B56 recruitment {#s2-2}
---------------------------------------------------------

At the centromere, Sgo1 and Sgo2 can both bind to PP2A-B56 ([@bib33]; [@bib41]; [@bib48]), but Sgo1 is considered the primary receptor because it is more important than Sgo2 for protecting cohesion in mitosis ([@bib12]; [@bib15]; [@bib16]; [@bib21]; [@bib25]; [@bib33]; [@bib40]; [@bib41]). However, this critical role in cohesin maintenance could also be explained by PP2A- independent effects ([@bib9]). Furthermore, although Sgo1 has been implicated in PP2A-B56 recruitment to centromeres ([@bib19]; [@bib20]; [@bib28]; [@bib40]), the only study that has directly compared the contribution of Sgo1 and Sgo2 to centromeric PP2A-B56 recruitment, has concluded that Sgo2 is more important ([@bib16]). We therefore set out to clarify the role of Sgo1 and Sgo2 in controlling the recruitment of B56 isoforms to the centromere in human cells.

Depletion of Sgo2, but not Sgo1, caused a significant reduction in B56α levels at the centromere ([Figure 2a--d](#fig2){ref-type="fig"}). It is important to note that the quantification in [Figure 2b and d](#fig2){ref-type="fig"} cannot distinguish between kinetochore and centromere localisation, and whilst Sgo1 depletion did not reduce B56, it did appear to shift its localisation towards the kinetochore (see zoom panel in [Figure 2c](#fig2){ref-type="fig"}), an effect that has previously been seen by others ([@bib26]). Line plots analysis, which can quantify localisation across the centromere-kinetochore axis, demonstrates that Sgo1 depletion caused Sgo2 and B56α to spread out from the centromere towards the kinetochore ([Figure 2e](#fig2){ref-type="fig"}). This is due to inefficient anchoring of Sgo2 at centromeres because combined Sgo1 and Sgo2 depletion completely removed B56α from kinetochores and centromeres ([Figure 2f,g](#fig2){ref-type="fig"}). We therefore conclude that, as suggested previously by others ([@bib16]), Sgo2 is the primary centromeric receptor for PP2A-B56 during mitosis. However, Sgo1 also contributes to centromeric B56 localisation primarily by helping to anchor the Sgo2-B56 complex at the centromere, perhaps by bridging an interaction with cohesin rings or by helping to preserve centromeric cohesion ([@bib9]; [@bib20]).

![Sgo2 specifically localizes B56α to centromeres.\
(**A-G**) The effect of Sgo1 and/or Sgo2 knockdown on YFP-B56α localisation in Flp-in HeLa cells. Representative images (**A, C, F**) and quantifications (**B, D, G**) of relative kinetochore intensity of B56α in cells arrested in prometaphase with nocodazole after knockdown of Sgo2 (**A, B**), Sgo1 (**C, D**), or Sgo1 +Sgo2 (**F, G**). (**E**) shows line plots of Sgo2 and B56α localisation following Sgo1 knockdown; 5 kinetochore pairs were analysed per cell, for a total of 10 cells per experiment. Graphs represent the mean intensities (±SD) from 3 independent experiments. Intensity is normalized to the maximum signal present in each channel within the endogenous B56α experiment. (**H--M**) Flp-in HeLa cells expressing YFP-B56α or YFP-B56γ were transfected with the CB-Sgo2 (**H--K**) or gChr7 +Cas9 DARPIN (**L, M**) and analysed for B56 recruitment in cells arrested in prometaphase with nocodazole. (**H**), (**L**), and **J**). are representative images; **I**) and **K**) are quantifications of relative centromere/kinetochore intensity of the indicated antigen; and **M**) is quantification of intensity of Sgo2 over B56 at the Chr7 locus. For all centromere/kinetochore intensity graphs, each dot represents a cell and 10 cells were quantified per experiment for at least 3 independent experiments. The spread of dots indicates the biological variation between individual cells and the errors bars display the variation between the experimental repeats (displayed as -/+SD of the experimental means). Asterisks indicate significance (Mann-Whitney test); ns p\>0.05, \*p≤0.05, \*\*\*\*p≤0.0001. Scale bars, 5µm.](elife-42619-fig2){#fig2}

We next examined whether specific binding to Sgo1 and/or Sgo2 could explain differential B56 isoform localisation. To address this, we artificially relocalized Sgo1 or Sgo2 to the inner kinetochore, by fusing it to the kinetochore-targeting domain of CENP-B (CB). This location was chosen, even though it partially overlaps with the endogenous centromeric B56 pool, because it is still accessible to Aurora B. This may be important because phosphorylation of Sgo2 by Aurora B has been proposed to be needed for B56 interaction ([@bib41]). Whereas CB-Sgo1 was able to localise additional B56α and B56γ to the inner kinetochore ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), CB-Sgo2 was only able to recruit additional B56α ([Figure 2h--k](#fig2){ref-type="fig"}). To confirm that endogenous Sgo2 displayed selectivity for specific B56 isoforms, we used a Designed Ankyrin Repeat Protein (DARPin) that can bind to GFP with high affinity ([@bib3]). The DARPin was fused to dCas9 to enable the selective targeting of YFP-tagged B56α or B56γ to a repetitive region on chromosome 7 (Chr7). This assay confirmed that only B56α, and not B56γ, was able to co-recruit endogenous Sgo2 to this region ([Figure 2l,m](#fig2){ref-type="fig"}). Considering Sgo2 is the primary centromeric receptor for B56 ([Figure 2a,b](#fig2){ref-type="fig"}) ([@bib16]), this provides an explanation for why only a subset of B56 isoforms localise to the centromere.

Sgo1 collaborates with BubR1 to recruit B56 to kinetochores {#s2-3}
-----------------------------------------------------------

At the kinetochore, PP2A-B56 binds to a phosphorylated LxxIxE motif in BubR1 ([@bib17]; [@bib38]; [@bib49]) and this interaction is mediated by a binding pocket on B56 that is completely conserved in all isoforms ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) ([@bib10]; [@bib44]; [@bib45]). Therefore, we hypothesised that additional interactions may help to stabilise specific B56 isoforms at the kinetochore. In agreement with this hypothesis, BubR1 depletion or mutation of the LxxIxE binding pocket in B56γ (B56γ^H187A^) reduced but did not completely remove B56γ from kinetochores/centromere ([Figure 3a--d](#fig3){ref-type="fig"}). This is not due to knockdown efficiency or penetrance of the mutation, because residual B56 could still be detected after BubR1 depletion in B56γ^H187A^ cells ([Figure 3---figure supplement 1a,b](#fig3s1){ref-type="fig"}). Interestingly, the remaining B56γ in these situations spreads out between the kinetochore and centromere ([Figure 3e,f](#fig3){ref-type="fig"}), which implies that B56γ uses additional interactions to be maintained at this region.

![BubR1 and Sgo1 localize B56γ to kinetochores.\
B56γ kinetochore localisation in Flp-in HeLa cells after BubR1 knockdown (**A, B, E**) or mutation of the LxxIxE binding pocket (H187A: **C**), (**D, F**) in cells arrested in prometaphase with nocodazole. For each condition, representative images (**A, C**), quantification of relative centromere/kinetochore levels (**B, D**) and line plot analysis (**E, F**) depicts the levels and distribution of the indicated antigens. (**G--J**): representative images (**G, I**) and quantification of relative centromere/kinetochore intensities (**H, J**) YFP-B56γ WT or H187A following Sgo1 knockdown (**G, H**) or mutation of the Sgo1 binding region (ΔSgo1). For all centromere/kinetochore intensity graphs, each dot represents a cell and 10 cells were quantified per experiment from at least 3 independent experiments. The spread of dots indicates the biological variation between individual cells and the errors bars display the variation between experimental repeats (displayed as -/+SD of the experimental means). For the line plot analysis, 5 kinetochore pairs were analysed per cell, for a total of 10 cells per experiment. The graph represents the mean intensities (±SD) from at least 3 independent experiments. Intensity is normalized to the maximum signal in each channel in each experiment. Asterisks indicate significance (Mann-Whitney test); \*\*\*\*p≤0.0001. Scale bars, 5µm.](elife-42619-fig3){#fig3}

A targeted siRNA screen identified critical roles for Knl1 and Bub1, which, when depleted, completely abolished B56γ recruitment to kinetochores ([Figure 3---figure supplement 1c--f](#fig3s1){ref-type="fig"}). Knl1 recruits Bub1 to kinetochores, and Bub1 scaffolds the recruitment of BubR1 ([@bib13]; [@bib29]; [@bib31]). However, in addition to this, Bub1 also phosphorylates histone-H2A to localise Sgo1 to histone tails that are adjacent to the kinetochore ([@bib1]; [@bib14]; [@bib15]; [@bib19]; [@bib39]; [@bib50]). Since Sgo1 can bind to B56γ ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) we examined its role in the kinetochore recruitment of this isoform. Sgo1 depletion reduced B56γ^WT^ at kinetochores and completely removed B56γ^H187A^ ([Figure 3g,h](#fig3){ref-type="fig"}). Moreover, this was specific for Sgo1, because Sgo2 depletion had no effect ([Figure 3---figure supplement 1g,h](#fig3s1){ref-type="fig"}). To test whether this was due to direct binding to Sgo1, we generated a B56γ Sgo1-binding mutant (B56γ^ΔSgo1^), which we confirmed was defective in binding CB-Sgo1 in vivo ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). This mutation reduced the recruitment of B56γ^WT^ to kinetochores and completely abolished the recruitment of B56γ^H187A^ ([Figure 3i,j](#fig3){ref-type="fig"}), in a manner that was similar to the effect of Sgo1 depletion ([Figure 3g,h](#fig3){ref-type="fig"}). This demonstrates that Bub1 establishes two separate arms that cooperate to recruit B56γ to kinetochores: it binds directly to BubR1, which interacts via its LxxIxE motif with B56γ, and it phosphorylates Histone-H2A to recruit Sgo1, which additionally helps to anchor B56γ at kinetochores.

B56 isoforms bind differentially to LxxIxE containing motifs during mitosis {#s2-4}
---------------------------------------------------------------------------

The B56-Sgo1 interaction is unlikely to explain B56 isoform specificity at kinetochores, since Sgo1 interacts with both B56α and B56γ when recruited to centromeres ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). We therefore focussed on the LxxIxE interaction with BubR1 to quantitatively assess the binding to B56α and B56γ. Immunoprecipitations of equal amounts of B56α and B56γ from nocodazole-arrested cells demonstrated that BubR1 bound preferentially to B56γ ([Figure 4a,b](#fig4){ref-type="fig"}). Moreover, a panel of antibodies against other LxxIxE containing proteins ([@bib10]), demonstrated that LxxIxE binding was generally reduced in B56α immunoprecipitates ([Figure 4a,b](#fig4){ref-type="fig"}). B56γ has been shown to display slightly higher affinities for some LxxIxE containing peptides in vitro ([@bib46]), which, in principle, could allow this isoform to outcompete B56α for binding. However, a simple competition model is unlikely to explain differential kinetochore localisation, since we observe no change in B56α localisation when all other B56 isoforms are present or knocked down ([Figure 4c,d](#fig4){ref-type="fig"}). Instead, we favour the hypothesis that binding to LxxIxE motifs is specifically perturbed in PP2A-B56α complexes during prometaphase.

![Specific binding of B56γ to kinetochores reflects an enhanced ability to bind LxxIxE motifs.\
(**A**) Immunoblot of the indicated proteins, containing a LxxIxE motif ([@bib10]), following YFP immunoprecipitation from nocodazole-arrested Flp-in HeLa cells expressing YFP-B56α or YFP-B56γ. (**B**) Quantification of the mean normalised intensity (+SD) of the indicated antigens in B56α immunoprecipitates, relative to B56γ immunoprecipitates, from at least 3 independent experiments. Representative images (**C**) and line plot analysis (**D**) of YFP-B56α in Flp-in HeLa cells arrested in nocodazole and treated with the indicated siRNA. Each line plot graph represents the mean intensities (±SD) from 3 independent experiments. 5 kinetochore pairs were analysed per cell, for a total of 10 cells per experiment. Intensity is normalized to the maximum signal in each channel in each experiment. Asterisks indicate significance (Welch's t -test, unpaired); \*p≤0.05, \*\*p≤0.01, \*\*\*\*p≤0.0001. Scale bars, 5µm.](elife-42619-fig4){#fig4}

Residues within a C-terminal loop of B56 determine localisation to the centromere or kinetochore {#s2-5}
------------------------------------------------------------------------------------------------

We next searched for the molecular explanation for differential B56 isoform localisation. To do this, we generated four chimaeras between B56α and B56γ by joining the isoforms in the loops that connect the α-helixes ([Figure 5a](#fig5){ref-type="fig"}). Immunofluorescence analysis demonstrated that B56γ localisation switched from kinetochores to centromeres in chimaera 4 ([Figure 5b,c](#fig5){ref-type="fig"}). Furthermore, this region alone (i.e. the region that is different between chimaeras 3 and 4) is sufficient to switch localisation to the centromere when transferred into B56γ, and the corresponding region in B56γ can induce localisation to the kinetochore if transplanted into B56α ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). We generated four additional chimaeras to narrow down this region even further to amino acids 405--425 in B56α, which contains an α-helix and a small loop that juxtaposes the catalytic domain in the PP2A-B56γ complex ([Figure 5d--f](#fig5){ref-type="fig"}) ([@bib47]). Importantly, switching just four amino acids within this loop in B56α to the corresponding residues in B56γ (B56α^TKHG^) was sufficient to relocalise B56α from centromeres to kinetochores ([Figure 5g--i](#fig5){ref-type="fig"}). Furthermore, the B56α^TKHG^ remained functional and holoenzyme assembly was unperturbed ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). In summary, a small C-terminal loop in B56 defines whether B56 localises to centromeres, via Sgo2, or to kinetochores, via an LxxIxE interaction with BubR1.

![A C-terminal loop in B56 specifies B56 localization to centromeres or kinetochores.\
B56 localisation in B56α-γ chimaeras spanning the entire B56 (Ch1-4: **A--C**), a region at the C-terminus (Ch4a-4d: **D--F**). (**A, D**) Schematic representation of the B56α-γ chimaeras created. Representative images (**B, E**) and line plot analysis (**C, F**) to show the B56 localisation pattern in each chimaera. (**G**). Alignment of B56 isoforms within region 4d that controls centromere/kinetochore localisation. (**G--H**): Effect of 4 point-mutations within region 4d to convert B56α to the correspond B56γ sequence (B56α^TKHG^). Representative images (**H**) and line plot analysis (**I**) of B56α WT or B56α^TKHG^ in cells arrested in prometaphase with nocodazole. Each graph represents the mean intensities (±SD) from 3 independent experiments. 5 kinetochore pairs were analysed per cell, for a total of 10 cells per experiment. Intensity is normalized to the maximum signal in each channel in each experiment. Scale bars, 5µm.](elife-42619-fig5){#fig5}

The C-terminal loop controls Sgo2 binding and LxxIxE motif affinity {#s2-6}
-------------------------------------------------------------------

We next addressed whether the B56α^TKHG^ mutant switched the Sgo2 and LxxIxE binding properties of B56α. In-cell interaction assays demonstrated that B56α^TKHG^, in contrast to B56α^WT^, was not efficiently recruited to the centromere by CB-Sgo2 ([Figure 6a,b](#fig6){ref-type="fig"}), and was unable to co-recruit endogenous Sgo2 to the repeat region on chromosome 7, when re-localised there using dCas9-DARPin ([Figure 6c,d](#fig6){ref-type="fig"}). Furthermore, in addition to these effects on Sgo2 interaction, the YFP-B56α^TKHG^ mutant showed an enhanced ability to bind LxxIxE containing proteins and, in particular, BubR1, following immunoprecipitation from nocodazole-arrested cells ([Figure 6e,f](#fig6){ref-type="fig"}). Therefore, we conclude that the small EPVA loop in B56α is necessary for the interaction with Sgo2 and the centromere and, in addition, it is also required to fully repress binding to LxxIxE motifs and the kinetochore. Importantly, this loop is not sufficient to induce either of these effects when transplanted alone into B56γ, because B56γ^EPVA^ is not lost from the kinetochore or gained at the centromere ([Figure 6---figure supplement 1a](#fig6s1){ref-type="fig"}). Instead, a region immediately C-terminal to the EPVA (amino acids 414--453 in B56α) is also required to induce centromere binding, and a small helix N-terminal to the EPVA (amino acids 374--386 in B56α) is needed to repress kinetochore binding ([Figure 6---figure supplement 1b](#fig6s1){ref-type="fig"}). Therefore, although the regions that define centromere and kinetochore localisation overlap at the EPVA loop, they have different distal requirements that demonstrates that they are not identical ([Figure 6g](#fig6){ref-type="fig"}).

![A C-terminal loop in B56 regulates binding to Sgo2 and LxxIxE motifs to specify centromere/kinetochore localisation.\
(**A-D**) Flp-in HeLa cells expressing either YFP-B56α WT or TKHG were transfected with the CB-Sgo2 and analysed for B56 recruitment (**A, B**) or gChr7 +dCas9 DARPIN to assess YFP-B56α:Sgo2 co-localisation (**C, D**). Representative images (**A, C**) and quantification of relative kinetochore intensity (**B**) or intensity of Sgo2 over B56α at the Chr7 locus (**D**). For the intensity graphs in **B**) and **D**), each dot represents a cell and 10 cells were quantified per experiment from at least 3 independent experiments. The spread of dots indicates the biological variation between individual cells and the errors bars display the variation between experimental repeats (displayed as -/+SD of the experimental means). (**E**) Immunoblot of the indicated antigens following immunoprecipitation of YFP from nocodazole-arrested Flp-in HeLa cells expressing YFP- B56γ, YFP-B56α WT or YFP-B56α-TKHG. (**F**) Quantification of the mean normalised intensity (+SD) of indicated antigens in B56α WT or B56α TKHG immunoprecipitates, relative to B56γ, from at least 4 experiments. (**G**) Crystal structure of PP2A-B56γ \[accession code 2NPP ([@bib47])\] with annotation to indicate the regions that specify localisation to centromeres or kinetochores (see [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} for details of the additional centromere/kinetochore specification regions). Note, the structure is meant only as a guide because the critical regions may be present within B56α, which has not been structurally solved. The B56α WT values are also used in some of the points plotted in [Figure 2m](#fig2){ref-type="fig"}. Asterisks indicate significance (Mann-Whitney test, except [Figure 6f](#fig6){ref-type="fig"}: Welch's t -test, unpaired); ns p\>0.05, \*p≤0.05, \*\*p≤0.01, \*\*\*p≤0.001, \*\*\*\*p≤0.0001. Scale bars, 5µm.](elife-42619-fig6){#fig6}

Discussion {#s3}
==========

This work demonstrates how different B56 isoforms localise to discrete subcellular compartments to control separate processes during mitosis. Differential B56 isoform localisation has previously been observed in interphase ([@bib24]) and during the later stages of mitosis ([@bib2]), which implies that B56 isoforms may have evolved to carry out specific functions, at least in part, by targeting PP2A to distinct subcellular compartments. The differential localisation we observe during prometaphase arises because B56 isoforms display selectivity for specific receptors at the centromere and kinetochore.

The centromeric isoform B56α binds preferentially to Sgo2 via a C-terminal stretch that lies between amino acids 405 and 453 ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). A key loop within this region juxtaposes the catalytic domain and contains an important EPVA signature that is critical for Sgo2 binding and is unique to B56α and B56ε. This sequence is also conserved in *Xenopus* B56ε, which has previously been shown to selectively bind to Sgo2, when compared to B56γ ([@bib33]). We therefore propose that a subset of B56 isoforms (B56α and ε) utilize unique motifs to interact with Sgo2 and the centromere during mitosis.

How then can these results be reconciled with the fact that Sgo1 appears to be more important than Sgo2 for the maintenance of cohesion during mitosis ([@bib12]; [@bib15]; [@bib16]; [@bib21]; [@bib25]; [@bib33]; [@bib39]; [@bib40]; [@bib41])? Firstly, it is important to note that Sgo1 can compete with the cohesin release factor, WAPL, for cohesin binding ([@bib9]), thereby protecting cohesion independently of PP2A. In addition, Sgo1 could help cells to tolerate the loss of Sgo2, because Sgo2 depletion does not fully remove PP2A-B56 from the centromere, and the pool that remains under these conditions is dependent on Sgo1 ([Figure 2a--g](#fig2){ref-type="fig"}). Therefore, the residual Sgo1-PP2A-B56α/ε that remains at centromeres following Sgo2 depletion could be sufficient to preserve cohesion. Finally, Sgo1 is needed to preserve Sgo2-PP2A-B56 at the centromere ([Figure 2e](#fig2){ref-type="fig"}) and it can also bind directly to the SA2--Scc1 complex ([@bib9]; [@bib20]; [@bib41]). Therefore, perhaps Sgo1 also helps to position Sgo2-PP2A-B56 so that it can dephosphorylate nearby residues within the cohesin complex. It will be important in future to examine the interplay between Sgo1, Sgo2 and PP2A-B56 at centromeres.

The kinetochore B56 isoforms bind to BubR1 via a canonical LxxIxE motif within the KARD ([@bib10]; [@bib17]; [@bib38]; [@bib49]). Although the LxxIxE binding pocket is completely conserved in all B56 isoforms ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), we observe a striking preference in the binding of B56γ over B56α to many LxxIxE containing proteins during prometaphase ([Figure 4](#fig4){ref-type="fig"}). We hypothesise that this is due to repressed binding between LxxIxE motifs and B56α during prometaphase, because LxxIxE binding ([Figure 6e,f](#fig6){ref-type="fig"}) and kinetochore accumulation ([Figure 5h,j](#fig5){ref-type="fig"}) can both be enhanced by mutation of the EPVA loop in B56α (B56α^TKHG^). We cannot, however, exclude the possibility that the corresponding TKHG sequence in B56γ positively regulates LxxIxE interaction and kinetochore localisation. Considering that this region also controls Sgo2 and centromere binding, a simple explanation could be that Sgo2 interaction obscures the LxxIxE binding pocket. However, this appears unlikely for four reasons: 1) Sgo2 depletion does not relocalise B56α to kinetochores ([Figure 2a,b](#fig2){ref-type="fig"}), 2) Sgo2 depletion does not enhance the ability of B56α to bind to BubR1 or other LxxIxE motifs during mitosis ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}), 3) centromere and kinetochore binding can occur together in certain B56α-γ chimaeras ([Figure 6---figure supplement 1b](#fig6s1){ref-type="fig"}), and 4) the regions that define each of these localisations do not fully overlap ([Figure 6g](#fig6){ref-type="fig"}). Although we believe these results imply that Sgo2 is unlikely to block LxxIxE interaction, in vitro experiments with purified components would ultimately be needed to formally rule this out. If not Sgo2, then what could limit the kinetochore accumulation of B56α? We speculate that another interacting partner, or alternatively a tail region within a PP2A-B56 subunit, might obscure or modify the conformation of the LxxIxE binding pocket in PP2A-B56α complexes.

An important additional finding of this work is that Sgo1 contributes to the B56γ signal observed at the kinetochore ([Figure 3g--j](#fig3){ref-type="fig"}). This likely requires Sgo1 to be bound to histone tails, because it also depends on Bub1, the kinase that phosphorylates histone H2A to recruit Sgo1 ([@bib1]; [@bib14]; [@bib15]; [@bib19]; [@bib39]; [@bib50]) ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). It is not currently clear whether a Sgo1:PP2A-B56γ complex simply contributes to the signal observed at kinetochores or whether it may help to physically retain BubR1:PP2A-B56 at the kinetochore, for example, by directly interacting with the BubR1:PP2A-B56 complex. The interfaces between BubR1-B56 and Sgo1-PP2A-B56 do not appear to be overlapping, at least based on current structural data ([@bib44]; [@bib45]; [@bib48]), which implies that Knl1-bound BubR1-B56 could potentially be anchored towards histone tails by Sgo1. We were unable to detect Sgo1 in YFP-BubR1 immunoprecipitates (results not shown), however, this could simply reflect an interaction that is either transient or unstable away from kinetochores. It will be important in future to clarify exactly how Sgo1 collaborates with BubR1 to control B56 localisation and, in particular, to determine whether Sgo1 can interact with BubR1:PP2A-B56 complexes directly. If such a complex can exist, then this could have important implications for SAC signalling and tension-sensing.

In summary, the work presented here explains how different members of the PP2A-B56 family function during the same stage of mitosis to control different biological processes. This is the first time that such sub-functionalisation has been demonstrated between isoforms of the same B family. It is currently unclear why such specialisation is necessary or at least preferable to a situation whereby all B56 isoforms operate redundantly, as initially suggested ([@bib8]). One possibility is that the use of different B56 isoforms allows PP2A catalytic activity to be regulated differently in specific subcellular compartments: for example, by enabling interactions or post-translational modifications that are specific for the B56 subunits. In this respect, protein inhibitors of PP2A-B56 have been shown to function specifically at the centromere (SET ([@bib4])) and at the kinetochore (BOD1 ([@bib30])); therefore, it would be interesting to test whether these inhibitors display selectivity for certain PP2A-B56 isoforms. Future studies such as this, which build upon the work presented here, may ultimately help to reveal novel ways to modulate the activity of specific PP2A-B56 complexes. The recent development of selective inhibitors of related PP1 regulatory isoforms to combat neurodegenerative diseases ([@bib6]; [@bib18]), provides a proof-of-concept that successful targeting of specific serine/threonine phosphatase isoforms is both achievable and therapeutically valuable.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\      Designation                      Source or reference                Identifiers                                                      Additional information
  or resource                                                                                                                                             
  ------------------ -------------------------------- ---------------------------------- ---------------------------------------------------------------- -----------------------------------------------------------
  Cell line\         HeLa Flp-in                      [@bib42]                                                                                            
  (*H.sapiens*)                                                                                                                                           

  Recombinant\       pcDNA5-YFP-B56\                  This paper                                                                                          B56 from pCEP-4xHA-B56\
  DNA reagent        α, β, γ~1~, γ~3~, δ and ε.                                                                                                           (Addgene 14532--14537) cloned\
                                                                                                                                                          into pcDNA5-LAP-BubR1WT\
                                                                                                                                                          ([@bib27]),\
                                                                                                                                                          Not1-Apa1 sites.

  Recombinant DNA\   pcDNA5-YFP-B56α−(TKHG)           This paper                                                                                          Site-directed mutagenesis of\
  reagent                                                                                                                                                 pcDNA5-YFP-B56α: E405T, P409K,\
                                                                                                                                                          V412H, A413G

  Recombinant DNA\   pcDNA5-YFP-B56α-(γ4)             This paper                                                                                          See\
  reagent                                                                                                                                                 [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}

  Recombinant DNA\   pcDNA5-YFP-B56γ-H187A            This paper                                                                                          Site-directed mutagenesis\
  reagent                                                                                                                                                 of pcDNA5-YFP-B56γ

  Recombinant DNA\   pcDNA5-YFP-B56γ-ΔSgo1            This paper                                                                                          Site-directed mutagenesis of\
  reagent                                                                                                                                                 pcDNA5-YFP-B56γ: Y391F, L394S,\
                                                                                                                                                          M398Q.

  Recombinant DNA\   pcDNA5-YFP-B56γ-H187A-ΔSgo1      This paper                                                                                          Site-directed mutagenesis of\
  reagent                                                                                                                                                 pcDNA5-YFP-B56γ-H187A: Y391F,\
                                                                                                                                                          L394S, M398Q.

  Recombinant DNA\   pcDNA5-YFP-B56γ-(α4)             This paper                                                                                          See\
  reagent                                                                                                                                                 [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}

  Recombinant DNA\   pcDNA5-YFP-B56γ-(α4.1)           This paper                                                                                          See\
  reagent                                                                                                                                                 [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}

  Recombinant DNA\   pcDNA5-YFP-B56γ-(α4.2)           This paper                                                                                          See\
  reagent                                                                                                                                                 [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}

  Recombinant DNA\   pcDNA5-YFP-B56γ-(α4.3)           This paper                                                                                          See\
  reagent                                                                                                                                                 [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}

  Recombinant DNA\   pcDNA5-YFP-B56γ−(EPVA)           This paper                                                                                          Site-directed mutagenesis of\
  reagent                                                                                                                                                 pcDNA5-YFP-B56γ: T631E, K635P,\
                                                                                                                                                          H638V, G639A.

  Recombinant DNA\   pcDNA5-YFP-B56-Ch1               This paper                                                                                          See [Figure 5](#fig5){ref-type="fig"}.
  reagent                                                                                                                                                 

  Recombinant DNA\   pcDNA5-YFP-B56-Ch2               This paper                                                                                          See [Figure 5](#fig5){ref-type="fig"}.
  reagent                                                                                                                                                 

  Recombinant DNA\   pcDNA5-YFP-B56-Ch3               This paper                                                                                          See [Figure 5](#fig5){ref-type="fig"}.
  reagent                                                                                                                                                 

  Recombinant DNA\   pcDNA5-YFP-B56-Ch4               This paper                                                                                          See [Figure 5](#fig5){ref-type="fig"}.
  reagent                                                                                                                                                 

  Recombinant DNA\   pcDNA5-YFP-B56-Ch4a              This paper                                                                                          See [Figure 5](#fig5){ref-type="fig"}.
  reagent                                                                                                                                                 

  Recombinant DNA\   pcDNA5-YFP-B56-Ch4b              This paper                                                                                          See [Figure 5](#fig5){ref-type="fig"}.
  reagent                                                                                                                                                 

  Recombinant DNA\   pcDNA5-YFP-B56-Ch4c              This paper                                                                                          See [Figure 5](#fig5){ref-type="fig"}.
  reagent                                                                                                                                                 

  Recombinant DNA\   pcDNA5-YFP-B56-Ch4d              This paper                                                                                          See [Figure 5](#fig5){ref-type="fig"}.
  reagent                                                                                                                                                 

  Recombinant DNA\   pcDNA5-vsv-CENP-\                This paper                                                                                          PCR Sgo2 from pDONR-Sgo2\
  reagent            B-Sgo2-mCherry                                                                                                                       (gift T.J.Yen) into pcDNA5-vsv-\
                                                                                                                                                          CENP-B-Sgo1-mCherry

  Recombinant DNA\   pcDNA5-vsv-CENP-B-\              [@bib26]                                                                                            
  reagent            Sgo1-mCherry                                                                                                                         

  Recombinant DNA\   pHAGE-TO-dCas9-\                 This paper                                                                                          Progenitor plasmid: pHAGE-TO-\
  reagent            DARPIN-flag                                                                                                                          dCas9-3xmCherry (Addgene\
                                                                                                                                                          64108). 3xmCherry replaced with\
                                                                                                                                                          synthesised DARPIN-Flag\
                                                                                                                                                          ([@bib3]).

  Sequence-based\    gRNA targeting a\                [@bib5]                                                                                             GCTCTTATGGTGAGAGTGT
  reagent            repetetive region on\                                                                                                                
                     chromosome 7                                                                                                                         

  Sequence-based\    B56 Knockin gRNAs                This paper                                                                                          B56a: gatgtcgtcgtcgtcgccgccgg.\
  reagent                                                                                                                                                 B56g: gtcaacatctagacttcagcggg

  Sequence-based\    siRNAs                           [@bib8]                                                                                             B56α (PPP2R5A),\
  reagent                                                                                                                                                 5'-UGAAUGAACUGGUUGAGUA-3';\
                                                                                                                                                          B56β (PPP2R5B),\
                                                                                                                                                          5'-GAACAAUGAGUAUAUCCUA-3';\
                                                                                                                                                          B56γ (PPP2R5C),\
                                                                                                                                                          5'-GGAAGAUGAACCAACGUUA-3';\
                                                                                                                                                          B56δ (PPP2R5D),\
                                                                                                                                                          5'-UGACUGAGCCGGUAAUUGU-3';\
                                                                                                                                                          B56ε (PPP2R5E),\
                                                                                                                                                          5'-GCACAGCUGGCAUAUUGUA-3';

  Sequence-based\    siRNAs                           [@bib16]                                                                                            Sgo2,\
  reagent                                                                                                                                                 5'-GCACUACCACUUUGAAUAA-3';

  Sequence-based\    siRNAs                           Dharmacon, J-015475--12                                                                             Sgo1,\
  reagent                                                                                                                                                 5'-GAUGACAGCUCCAGAAAUU-3';

  Sequence-based\    siRNAs                           [@bib27]                                                                                            BubR1,\
  reagent                                                                                                                                                 5'-AGAUCCUGGCUAACUGUUC-3'

  Sequence-based\    siRNAs                           [@bib43]                                                                                            Knl1,\
  reagent                                                                                                                                                 5'-GCAUGUAUCUCUUAAGGAA-3';\
                                                                                                                                                          Bub1\
                                                                                                                                                          5'-GAAUGUAAGCGUUCACGAA-3';

  Sequence-based\    siRNAs                           Dharmacon (D-001830)                                                                                Control (GAPDH),\
  reagent                                                                                                                                                 5'-GUCAACGGAUUUGGUCGUA-3'

  Antibody           Mouse monoclonal\                Peter Parker, Francis\                                                                              1:1000
                     anti-GFP (clone 4E12/8[)]{.ul}   Crick Institute                                                                                     

  Antibody           Chicken polyclonal\              Abcam                              Abcam: ab13970,\                                                 1:5000
                     anti-GFP                                                            RRID:[AB_300798](https://scicrunch.org/resolver/AB_300798)       

  Antibody           Mouse monoclonal\                Abnova                             Abnova:\                                                         1:1000
                     anti-Sgo1 (clone 3C11)                                              H001516480M01                                                    

  Antibody           Rabbit polyclonal\               Bethyl                             Bethyl:\                                                         1:1000
                     anti-Sgo2                                                           A301-262A,\                                                      
                                                                                         RRID:[AB_890650](https://scicrunch.org/resolver/AB_890650)       

  Antibody           Mouse monoclonal\                EMD Millipore                      EMD Millipore:\                                                  1:1000
                     anti-BubR1 (clone 8G1)                                              05--898,\                                                        
                                                                                         RRID:[AB_417374](https://scicrunch.org/resolver/AB_417374)       

  Antibody           Mouse monoclonal\                Sigma                              Sigma: V5507,\                                                   1:1000
                     anti-VSV (clone P5D4)                                               RRID:[AB_261877](https://scicrunch.org/resolver/AB_261877)       

  Antibody           Rabbit polyclonal\               Abcam                              Abcam:\                                                          1:1000
                     anti-Knl1                                                           ab70537,\                                                        
                                                                                         RRID:[AB_1209410](https://scicrunch.org/resolver/AB_1209410)     

  Antibody           Rabbit polyclonal\               Bethyl                             Bethy;l:\                                                        1:1000
                     anti-Bub1                                                           A300-373A,\                                                      
                                                                                         RRID:[AB_2065943](https://scicrunch.org/resolver/AB_2065943)     

  Antibody           Mouse monoclonal\                Sigma                              Sigma: F3165,\                                                   1:10000
                     anti-FLAG (clone M2)                                                RRID:[AB_259529](https://scicrunch.org/resolver/AB_259529)       

  Antibody           Guinea Pig polyclonal\           MBL                                MBL: PD030                                                       1:5000
                     anti-Cenp-C                                                                                                                          

  Antibody           Rabbit polyclonal\               [@bib27]                                                                                            1:1000
                     anti-pMELT-Knl1\                                                                                                                     
                     (phospho-T943 and -\                                                                                                                 
                     T1155)                                                                                                                               

  Antibody           Rabbit polyclonal\               Geert Kops, Hubrecht\                                                                               1:5000
                     anti-GFP                         Institute                                                                                           

  Antibody           Mouse monoclonal\                Santa Cruz\                        Santa Cruz\                                                      1:1000
                     anti-B56γ (clone A-11)           Biotechnology                      Biotechnology:\                                                  
                                                                                         sc-374379,\                                                      
                                                                                         RRID:[AB_10988028](https://scicrunch.org/resolver/AB_10988028)   

  Antibody           Mouse monoclonal\                BD Biosciences                     BD Biosciences:\                                                 1:1000
                     anti-B56α (clone 23)                                                610615,\                                                         
                                                                                         RRID:[AB_397947](https://scicrunch.org/resolver/AB_397947)       

  Antibody           Mouse monoclonal\                Santa Cruz\                        Santa Cruz\                                                      1:1000
                     anti-B56δ (clone H-11)           Biotechnology                      Biotechnology:\                                                  
                                                                                         sc-271363,\                                                      
                                                                                         RRID:[AB_10611062](https://scicrunch.org/resolver/AB_10611062)   

  Antibody           Rabbit polyclonal\               Aviva                              Aviva:\                                                          1:1000
                     anti-B56ε                                                           ARP56694-P50                                                     

  Antibody           Mouse monoclonal\                EMD Millipore                      EMD Millipore:\                                                  1:5000
                     anti-PPP2CA\                                                        05--421,\                                                        
                     (clone 1D6)                                                         RRID:[AB_309726](https://scicrunch.org/resolver/AB_309726)       

  Antibody           Rabbit polyclonal\               Cell Signaling\                    Cell Signaling\                                                  1:1000
                     anti-PPP2R1A\                    Technology                         Technology: 2041,\                                               
                     (clone 81G5)                                                        RRID:[AB_2168121](https://scicrunch.org/resolver/AB_2168121)     

  Antibody           Rabbit polyclonal\               Bethyl                             Bethyl:\                                                         1:1000
                     anti-BubR1                                                          A300-386A,\                                                      
                                                                                         RRID:[AB_386097](https://scicrunch.org/resolver/AB_386097)       

  Antibody           Rabbit polyclonal\               Cell Signaling\                    Cell Signaling\                                                  1:1000
                     anti-Axin                        Technology                         Technology: C76H11,\                                             
                                                                                         RRID:[AB_2274550](https://scicrunch.org/resolver/AB_2274550)     

  Antibody           Rabbit polyclonal\               Abcam                              Abcam: ab155785                                                  1:1000
                     anti-GEF-H1                                                                                                                          

  Antibody           Rabbit polyclonal\               Bethyl                             Bethyl: A301-074A,\                                              1:1000
                     anti-Kif4A                                                          RRID:[AB_2280904](https://scicrunch.org/resolver/AB_2280904)     

  Antibody           Rabbit polyclonal\               Sigma                              Sigma: HPA030049,\                                               1:1000
                     anti-Repoman                                                        RRID:[AB_10600862](https://scicrunch.org/resolver/AB_10600862)   

  Antibody           Rabbit polyclonal\               Sigma                              Sigma: A2066,\                                                   1:5000
                     anti-Actin                                                          RRID:[AB_476693](https://scicrunch.org/resolver/AB_476693)       

  Antibody           Mouse monoclonal\                Sigma                              Sigma: T5168,\                                                   1:5000
                     anti-α-Tubulin\                                                     RRID:[AB_477579](https://scicrunch.org/resolver/AB_477579)       
                     (clone B-5-1-2)                                                                                                                      

  Antibody           Alexa-fluor488\                  ThermoFisher\                      Invitrogen: A11029,\                                             1:1000
                     anti-mouse                       Scientific                         RRID:[AB_138404](https://scicrunch.org/resolver/AB_138404)       

  Antibody           Alexa-fluor488\                  ThermoFisher\                      Invitrogen: A11034,\                                             1:1000
                     anti-rabbit                      Scientific                         RRID:[AB_2576217](https://scicrunch.org/resolver/AB_2576217)     

  Antibody           Alexa-fluor488\                  ThermoFisher\                      Invitrogen: A11039,\                                             1:1000
                     anti-chicken                     Scientific                         RRID:[AB_142924](https://scicrunch.org/resolver/AB_142924)       

  Antibody           Alexa-fluor488\                  ThermoFisher\                      Invitrogen: A11073,\                                             1:1000
                     anti-guinea pig                  Scientific                         RRID:[AB_142018](https://scicrunch.org/resolver/AB_142018)       

  Antibody           Alexa-fluor568\                  ThermoFisher\                      Invitrogen: A11031,\                                             1:1000
                     anti-mouse                       Scientific                         RRID:[AB_144696](https://scicrunch.org/resolver/AB_144696)       

  Antibody           Alexa-fluor568\                  ThermoFisher\                      Invitrogen: A11036,\                                             1:1000
                     anti-rabbit                      Scientific                         RRID:[AB_10563566](https://scicrunch.org/resolver/AB_10563566)   

  Antibody           Alexa-fluor647\                  ThermoFisher\                      Invitrogen: A21450,\                                             1:1000
                     anti-guinea pig                  Scientific                         RRID:[AB_141882](https://scicrunch.org/resolver/AB_141882)       

  Antibody           HRP-anti-mouse                   Bio-Rad                            Bio-Rad: 170--6516,\                                             1:2000
                                                                                         RRID:[AB_11125547](https://scicrunch.org/resolver/AB_11125547)   

  Antibody           HRP-anti-rabbit                  Bio-Rad                            Bio-Rad: 170--6515,\                                             1:5000
                                                                                         RRID:[AB_11125142](https://scicrunch.org/resolver/AB_11125142)   

  Chemical\          AZ-3146                          Selleckchem                        Selleckchem: S2731                                               
  compound, drug                                                                                                                                          

  Chemical\          Calyculin A                      LC labs                            LC labs: C-3987                                                  
  compound, drug                                                                                                                                          

  Chemical\          4,6-diamidino-2-\                Sigma                              Roche: 10236276001                                               
  compound, drug     phenylindole (DAPI)                                                                                                                  

  Chemical\          Dulbecco\'s Modified\            ThermoFisher\                      Gibco: 41966029                                                  
  compound, drug     Eagle Medium (DMEM)              Scientific                                                                                          

  Chemical\          Doxycycline hyclate              Sigma                              Sigma: D9891                                                     
  compound, drug                                                                                                                                          

  Chemical\          Fetal Bovine Serum               ThermoFisher\                      Life Technologies:\                                              
  compound, drug                                      Scientific                         10270106                                                         

  Chemical\          GFP-Trap magnetic\               Chromotek                          Chromotek: GTMA-20                                               
  compound, drug     beads                                                                                                                                

  Chemical\          Hygromycin B                     Santa Cruz\                        Santa Cruz\                                                      
  compound, drug                                      Biotechnology                      Biotechnology:\                                                  
                                                                                         sc-29067                                                         

  Chemical\          Lipofectamine\                   ThermoFisher\                      Invitrogen: 13778150                                             
  compound, drug     RNAiMax                          Scientific                                                                                          

  Chemical\          Nocodazole                       EMD Millipore                      EMD Millipore: 487928                                            
  compound, drug                                                                                                                                          

  Chemical\          MG132                            Selleckcem                         Selleckchem: S2619                                               
  compound, drug                                                                                                                                          

  Chemical\          Opti-MEM reduced\                ThermoFisher\                      Gibco: 31985--047                                                
  compound, drug     serum medium                     Scientific                                                                                          

  Chemical\          penicillin/streptomycin          ThermoFisher\                      Gibco: 15070--063                                                
  compound, drug                                      Scientific                                                                                          

  Chemical\          RO-3306                          Tocris                             Tocris: 4181                                                     
  compound, drug                                                                                                                                          

  Chemical\          Thymidine                        Sigma                              Sigma: T1895                                                     
  compound, drug                                                                                                                                          

  Software,\         Kinetochore quantification\      [@bib34]                                                                                            Software,
  algorithm          macro                                                                                                                                

  Algorithm          Multicolor Line\                 Kees Straatman (University\                                                                         
                     plot quantification\             of Leicester) with modification\                                                                    
                     macro                            by Balaji Ramalingam\                                                                               
                                                      (University of Dundee)                                                                              

  Software,\         Quantification of\               Image Studio Lite\                                                                                  
  algorithm          immunoblots                      (LI-COR Biosciences)                                                                                

  Software,\         Microscopy image\                Softworx software,\                                                                                 
  algorithm          processing                       GE Healthcare                                                                                       

  Software,\         Microscopy image\                ImageJ, National\                                                                                   
  algorithm          processing                       Institutes of Health                                                                                
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell culture and reagents {#s4-1}
-------------------------

HeLa Flp-in cells ([@bib42]), stably expressing a TetR, were authenticated by STR profiling (Eurofins) and cultured in DMEM supplemented with 9% tetracycline-free FBS, 50 μg/mL penicillin/streptomycin and 2 mM L-glutamine. All cell lines were routinely screened (every 4--8 weeks) to ensure they were free from mycoplasma contamination. All HeLa Flp-in cells stably expressing a doxycycline-inducible construct were derived from the HeLa Flp-in cell line by transfection with the pCDNA5/FRT/TO vector (Invitrogen) and the FLP recombinase, pOG44 (Invitrogen), and cultured in the same medium but containing 200 μg/mL hygromycin-B. Plasmids were transfected using Fugene HD (Promega) according to manufacturer's protocol. 1 µg/mL doxycycline was added for ≥16 hr to induce protein expression in the inducible cell lines. Thymidine (2 mM) and nocodazole (3.3 µM) were purchased from Millipore, MG132 (10 µM) and AZ-3146 from Selleck Chemicals, doxycycline (1 µg/mL) from Sigma, 4,6- diamidino-2-phenylindole (DAPI, 1:50000) from Invitrogen, calyculin A (10 µM in 10% EtOH) from LC labs, RO-3306 (10 µM) from Tocris and hygromycin-B from Santa Cruz Biotechnology.

Plasmids and cloning {#s4-2}
--------------------

pCDNA5-YFP -B56α, β, γ1, γ3, δ and ε were amplified from pCEP-4xHA-B56 (Addgene plasmids 14532--14537; deposited by D. Virshup, Duke-NUS Graduate Medical School, Singapore) and subcloned into pCDNA5-LAP-BubR1^WT^ ([@bib27]) through Not1 and Apa1 restriction sites. B56γ1 and B56γ3 were corrected to start on M1 and not 11, and the R494L mutation in B56γ3 was corrected. pCDNA5-YFP-B56α and pCDNA5-YFP-B56γ1 were made siRNA-resistant by site-directed mutagenesis (silent mutations in the coding sequence for E102 and L103 in B56α, and T126 and L127 in B56γ). All B56α and B56γ1 mutants were created by site-directed mutagenesis from pCDNA5-YFP-B56α and pCDNA5-YFP-B56γ1, respectively. The B56α--γ chimeras were generated by Gibson assembly with pCDNA5-YFP-B56α and pCDNA5-YFP-B56γ used as templates for the PCR reaction. vsv-CENP-B-Sgo1-mCherry ([@bib26]) was used to make vsv-CENP-B-Sgo2-mCherry, by removing Sgo1 and adding Sgo2 via Gibson assembly from pDONR-Sgo2 (a gift from T. J. Yen). The Sgo1 binding mutant in B56γ (B56γ ^ΔSgo1^) was created by site directed mutagenesis to create three mutations: Y391F, L394S and M398Q. The dCas9-DARPIN-flag was created by digesting pHAGE-TO-dCas9-3xmCherry (Addgene \#64108) with BamHI and XhoI to remove 3xmCherry and replace with a synthesised DARPIN-flag that binds to GFP with high affinity ([@bib3]). The gRNA targeting a repetitive region on chromosome seven was generated by PCR mutagenesis to introduce the gRNA sequence (GCTCTTATGGTGAGAGTGT ([@bib5])) into the pU6 vector.

Gene knockdowns {#s4-3}
---------------

Cells were transfected with 20 nM siRNA using Lipofectamine RNAiMAX Transfection Reagent (Life Technologies) according to the manufacturer's instructions. For simultaneous knockdown of all B56 isoforms (B56pool) the single B56 isoform siRNA were mixed at equimolar ratio of 20 nM each. The siRNA sequences used in this study are as follows: B56α (PPP2R5A), 5'-UGAAUGAACUGGUUGAGUA-3'; B56β (PPP2R5B), 5'-GAACAAUGAGUAUAUCCUA-3'; B56γ (PPP2R5C), 5'-GGAAGAUGAACCAACGUUA-3'; B56δ (PPP2R5D), 5'-UGACUGAGCCGGUAAUUGU-3'; B56ε (PPP2R5E), 5'-GCACAGCUGGCAUAUUGUA-3'; Sgo1, 5'-GAUGACAGCUCCAGAAAUU-3'; Sgo2, 5'-GCACUACCACUUUGAAUAA-3'; BubR1, 5'-AGAUCCUGGCUAACUGUUC-3'; Knl1, 5'-GCAUGUAUCUCUUAAGGAA-3'; Bub1 5'-GAAUGUAAGCGUUCACGAA-3'; Control (GAPDH), 5'-GUCAACGGAUUUGGUCGUA-3';. All siRNA oligos were custom made and purchased from Sigma, except for Sgo1, which was ordered from Dharmacon (J-015475--12).

Expression of B56 isoforms {#s4-4}
--------------------------

For reconstitution of B56 isoforms or mutants, HeLa Flp-in cells were transfected with 100 nM B56pool or mock siRNA and, in some experiments, 20 nM additional control, Sgo1, Sgo2, BubR1, Bub1 or Knl1 siRNA. Cells were transfected with the appropriate siRNA for 16 hr, after which they were arrested in S phase for 24 hr by addition of thymidine. Subsequently, cells were released from thymidine for 8--10 hr and arrested in prometaphase by the addition of nocodazole. YFP-B56 expression was induced by the addition of doxycycline during and following the thymidine block. For BubR1 knockdowns and for all chromosome alignment assays, cells were released from thymidine for 6.5 hr and arrested at the G2/M boundary with RO3306 for 2 hr. Cells were then released into nocodazole (BubR1 experiments) or normal growth media (alignment assays) for 15 mins before MG132 was then added for 30 mins to prevent mitotic exit. For alignment assays, this is critical to analyse the synchronous alignment of mitotic cells over a 45 min period.

Chromosome spreads to analyse centromeric cohesion {#s4-5}
--------------------------------------------------

Hela-FRT cells were transfected with B56pool, B56βγδε, B56αγδε or control siRNA for 16 hr, treated with thymidine for 24 hr and released into normal growth media for 6.5 hr. Cells were then arrested at the G2/M boundary with RO3306 for 2 hr before release into nocodazole for 1 hr. Mitotic cells were isolated and incubated with hypotonic buffer (20 mM Hepes (pH7.0), 1 mM MgCl~2~, 20 mM KCl, 2 mM CaCl~2~) for 10 min at room temperature before being spun onto slides using a Cellspin cytocentrifuge (Tharmac). Slides were airdried for 1 min and then fixed in 4% formaldehyde in PBS for 10 min at room temperature. Blocking and immunofluorescence staining (for Cenp-C to visualise split kinetochore pairs) was carried out as described below. The percentage of cells with at least one split sister kinetochore pair was quantified.

In-cell protein-protein interaction assay using dCas9 or CB-Sgo1/2 {#s4-6}
------------------------------------------------------------------

Cells were transfected with dCas9-DARPIN-flag and a guide RNA that targets a repetitive region on chromosome 7 (at 1:3 ratio of dCas9:gRNA). Doxycycline was added to induce YFP-B56 isoform expression and 48 hr later cells arrested in mitosis with nocodazole were fixed, stained and imaged for co-localisation of YFP-B56 isoforms and Sgo2. Only cells containing defined Flag-dCas9 spots that also co-recruited YFP-B56 were imaged. The majority of these spots recruited YFP-B56, but the dCas9 spots themselves were only readily detectable in mitotic cells. For the CB-Sgo1/2 expression experiments, the endogenous Sgo1/2 was still present during these assays.

CRISPR/Cas9 knock-in {#s4-7}
--------------------

800 base pair homology arms that span left and right of the start codon of B56α and B56γ were custom synthetized by Biomatik. A NaeI (B56γ)/SwaI (B56α) restriction site was place between the homology arms and used to insert a YFP tag by Gibson assembly. Guides were designed to span the start codon (using <http://crispr.mit.edu/>) so that their complementary sequences are interrupted following successful homologous recombination. Flp-in HeLa Cas9 cells were generated and transfected with the YFP-homology arm vector and guide RNAs (B56α: gatgtcgtcgtcgtcgccgccgg B56γ: gtcaacatctagacttcagcggg) in a 1:1 ratio. Cas9 expression was then induced by addition of doxycycline and FACS was performed 2 weeks later to sort cells and enrich for the YFP-expressing population.

Live-cell imaging and immunofluorescence {#s4-8}
----------------------------------------

For time-lapse analysis, cells were plated in 24-well plates, transfected and imaged in a heated chamber (37°C and 5% CO2) using a 10x/0.5 NA on a Zeiss Axiovert 200M Imaging system, controlled by Micro-manager software (open source: <https://www.micro-manager.org/>). Images were acquired with a Hamamatsu ORCA-ER camera every 4 min using 2 × 2 binning. For immunofluorescence, cells were plated on High Precision 1.5H 12 mm coverslips (Marienfeld). Following the appropriate treatment, cells were pre-extracted with 0.1% Triton X-100 in PEM (100 mM Pipes, pH 6.8, 1 mM MgCl~2~ and 5 mM EGTA) for 1 min followed by addition of 4% PFA/PBS for 2 min; cells were subsequently fixed with 4% paraformaldehyde in PBS for 10 min. Coverslips were washed with PBS and blocked with 3% BSA in PBS + 0.5% Triton X-100 for 30 min, incubated with primary antibodies for 16 hr at 4°C, washed three times with PBS and incubated with secondary antibodies plus DAPI for an additional 2--4 hr at room temperature in the dark. Washed coverslips were then mounted on a glass slide using ProLong antifade reagent (Molecular Probes). All images were acquired on a DeltaVision Core or Elite system equipped with a heated 37°C chamber, with a 100x/1.40 NA U Plan S Apochromat objective using softWoRx software (Applied precision). Images were acquired at 1 × 1 binning using a CoolSNAP HQ2 camera (Photometrics) and processed using softWorx software and ImageJ (National Institutes of Health). All images displayed are maximum intensity projections of deconvolved stacks. All displayed immunofluorescence images were chosen to most closely represent the mean quantified data.

Image quantifications {#s4-9}
---------------------

For kinetochore quantification of immunostainings, all images within an experiment were acquired with identical illumination settings and analysed using ImageJ (for experiments in which ectopic proteins were expressed, cells with comparable levels of exogenous protein were selected for analysis). Kinetochore quantification was performed as previously ([@bib34]). For quantification of B56 localization, The Cenp-C channel was used to choose 5 random kinetochore pairs per cell that lie on the same 0.2 μm Z-plane. A line was then drawn through the kinetochore pairs (using ImageJ), with the first Cenp-C kinetochore peak at 0.2 µm from the start of the line. An ImageJ macro (created by Kees Straatman, University of Leicester and modified by Balaji Ramalingam, University of Dundee) was used to simultaneously measure the intensities in each channel across the line. The signal from the five kinetochore pairs was averaged and normalized to the maximum signal in each channel. For chromosome alignment assays, misalignments were score as mild (1 to 2 misaligned chromosomes), intermediate (3 to 5 misaligned chromosomes), and severe (\>5 misaligned chromosomes). For mitotic exit assays, time from entry into mitosis (defined by the rounding up of the cell) to mitotic exit (defined by the separation of the sister chromatids or flattening down of the cell in nocodazole +AZ-3146) were recorded for 50 cells. Data is presented as cumulative percentage of mitotic exit over time.

Immunoprecipitation and immunoblotting {#s4-10}
--------------------------------------

Flp-in HeLa cells were treated with thymidine and doxycycline for 24 hr and subsequently released into fresh media supplemented with doxycycline and nocodazole for 16 hr. Mitotic cells were isolated by mitotic shake off and lysed in lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 0.5% TX-100, 1 mM Na~3~VO~4~, 5 mM ß-glycerophosphate, 25 mM NaF, 10 nM Calyculin A and complete protease inhibitor containing EDTA (Roche)) on ice. The lysate was incubated with GFP-Trap magnetic beads (from ChromoTek) for 2 hr at 4°C on a rotating wheel in wash buffer (same as lysis Buffer, but without TX-100) at a 3:2 ratio of wash buffer:lysate. The beads were washed 3x with wash buffer and the sample was eluted according to the protocol from ChromoTek. Samples were them processed for SDS-Page and immunoblotting using standard protocols.

Quantification of immunoblots {#s4-11}
-----------------------------

For quantification of relative immunoprecipitation levels, scanned immunoblots were analyzed using Image Studio Lite (LI-COR Bioscences). A rectangle of the same size was drawn around each band and the intensity within the band (minus the background) was calculated. The immunoprecipitated protein was used as a control, and each band was normalized to it.

Antibodies {#s4-12}
----------

All antibodies were diluted in 3% BSA in PBS. The following primary antibodies were used for immunofluorescence imaging (at the final concentration indicated): mouse α-GFP (clone 4E12/8, a gift from P. Parker; 1:1000), chicken α-GFP (ab13970, Abcam; 1:5000), mouse α- Sgo1 (clone 3C11, H00151648-M01, Abnova; 1:1000), rabbit α-Sgo2 (A301-262A, Bethyl; 1:1000), mouse α-BubR1 (clone 8G1, 05--898, Upstate/Millipore; 1:1000), mouse α-VSV (clone P5D4, V5507, Sigma; 1:1000), rabbit α-Knl1 (ab70537, Abcam; 1:1000), rabbit α-Bub1 (A300-373A, Bethyl; 1:1000), mouse α-FLAG (clone M2, F3165, Sigma, 1:10000) guinea pig α-Cenp-C (PD030, MBL; 1:5000) and rabbit α-pMELT-Knl1 directed against T943 and T1155 of human Knl1 ([@bib27]), 1:1000). Secondary antibodies used were highly-cross absorbed goat α-rabbit, α-mouse, α-guinea pig or α-chicken coupled to Alexa Fluor 488, Alexa Fluor 568, or Alexa Fluor 647 (Life Technologies); all were used at 1:1000.

The following antibodies were used for western blotting (at the final concentration indicated): rabbit α-GFP (custom polyclonal, a gift from G. Kops; 1:5000), mouse α-B56γ (clone A-11, sc-374379, Santa Cruz Biotechnology; 1:1000), mouse α-B56α (clone 23, 610615, BD; 1:1000), mouse α-B56δ (clone H-11, sc-271363, Santa Cruz, 1:1000), rabbit α-B56ε (ARP56694-P050, Aviva, 1:1000), mouse α-PPP2CA (clone 1D6, 05--421, Millipore; 1:5000) and rabbit α-PPP2R1A (clone 81G5, \#2041, CST; 1:1000), rabbit α-BubR1 (A300-386A, Bethyl; 1:1000), rabbit α-Axin (C76H11, CST; 1:1000), rabbit α-GEF-H1 (155785, Abcam; 1:1000), rabbit α-Kif4a (A301-074A, Bethyl; 1:1000), rabbit α-RepoMan (HPA030049, Sigma; 1:1000) and rabbit α-Actin (A2066, Sigma; 1:5000) and mouse α-alpha-Tubulin (clone B-5-1-2, T5168, Sigma, 1:5000). Secondary antibodies used were goat α-mouse IgG HRP conjugate (Bio-Rad; 1:2000) and goat α-rabbit IgG HRP conjugate (Bio-Rad; 1:5000).

Statistical tests {#s4-13}
-----------------

Mann-Whitney U test was performed to compare experimental groups in all kinetochore/centromere quantification graphs, whereas two-tailed, unpaired t-test with Welch's correction was performed to compare experimental groups in all other graphs (using Prism seven software). The n numbers for kinetochore/centromere quantification statistics were derived from the individual cells (i.e. biological replicates), which were always from at least three separate experiments (i.e. technical replicates) with similar results. The n numbers for the statistics in all other graphs were defined by the number of experimental repeats. The SD bars displayed in each graph shows the variation between the means of the experimental repeats. The statistical comparisons most pertinent for the conclusions are shown in the figures and legends. The original data for all experiments displayed in graphs can be found in the raw data source file, which also contains the actual statistical values.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Division of labour between PP2A-B56 isoforms at the centromere and kinetochore\" for consideration by *eLife*. Your article has been reviewed by Andrea Musacchio as the Senior Editor and Reviewing Editor, and three reviewers. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

PP2A occurs mostly as a trimeric enzyme, consisting of a catalytic C-subunit, a scaffolding A-subunit and a regulatory B-subunit. The literature describes four types of structurally unrelated B subunits and their diversity is further augmented by the expression of isoforms. Five different genes encode for the B\' (B56) isoform of PP2A. They are highly similar in amino acid sequence suggesting that they share redundant functions. Yet, recent studies in human cells revealed that individual B56 isoforms display distinct localization patterns, i.e. they localize to either the kinetochore or the centromere. In the submitted manuscript, Vallardi et al., investigate the molecular mechanisms underlying this differential localisation and function. They identify a domain in B56 that is responsible for this and show that it modulates the interaction with proteins containing a short linear motif (SLiM). This is probably the most novel observation reported here. Other observations, for instance the role of Sgo2 as the main receptor for centromeric PP2A-B56, are known from previous work (Kitajima et al., 2006), but the present study is systematic and provides a more comprehensive picture. Collectively, the work was praised for being systematic and because it sheds light on the molecular basis of a poorly understood phenomenon. While the analysis is generally strong, a major concern and several other points were discussed.

Essential revisions:

A point emerged strongly in the post-review discussion, namely that quantitative evidence corroborating claims on the role of the newly identified sequence motifs would not simply be nice to have but would strongly reinforce the paper. An analysis in vitro with purified B56a and B56g and peptides containing the relevant sequence motifs should aim to assess whether Sgo2 reduces the binding of B56a to BubR1, whether Sgo1 binds directly to Bubr1-B56, and whether these interactions are affected by mutation of the EPVA or TKHG motifs. Based on a significant body of previous work, we believe that these experiments are feasible and can be carried out in a time compatible with an *eLife* revision.

Other important points:

For some intensity plots, the authors indicate if the observed differences are significant or not (Figure 2, Figure 3B and D, Figure 2---figure supplement 1, Figure 3---figure supplement 2, Figure 6) but for others they do not (Figure 3H and J, Figure 3---figure supplement 1). Please add this information to all the plots.

In some of the presented images, a clear-cut centromeric or kinetochore localization of B5a and B56g, respectively, as compared to the marker proteins Sgo2 and CENP-C, was not immediately recognisable (see for example Figure 1B). This is particularly true for endogenously tagged B56g, which is almost equally abundant at kinetochores and centromeres (see Figure 1---figure supplement 3D). At the very least, the partially overlapping localisation should be acknowledged.

Kinetochore associated B56g, but not centromeric B56a, was sufficient to maintain the kinetochore functions of PP2A-B56 after the knockdown of all other B56 isoforms. The authors should explicitly state here that this cannot be explained by a lower expression level of B56a in these cells, as is only shown later in Figure 4A (but never commented upon). The reverse experiment, addressing whether B56a alone, but not B56g, can maintain the centromeric functions of PP2A-B56 is lacking and the authors could elect to carry it out.

The relative kinetochore intensity (e.g. Figure 1---figure supplement 5C) apparently refers to the combined kinetochore + centromere targeting. The normalised kinetochore intensity then shows the distribution between kinetochores and centromeres (e.g. Figure 1---figure supplement 5D). The y-axes should be re-defined to make this difference clear.

Figure 1---figure supplement 2. Please include the WB for the other B56 isoforms.

In Figure 2 and Figure 2---figure supplement 1Figure, the authors aim to demonstrate that specific binding of B56a to Sgo2 contributes to its centromeric localization. With these figures, the following problems were identified:

Figure 2C: Upon Sgo1 depletion, B56a seems to change its localization from a primarily centromeric localization to a primarily kt localization. Yet, this is not reflected in the quantifications shown in Figure 2D and 2E. Furthermore, Figure 2D gives the impression that Sgo1 is very efficiently depleted in Sgo1RNAi cells. The IF image shown in C gives a different impression. Could the authors please comment on this?

Subsection "Sgo2 provides specificity for centromeric B56 recruitment": \"..., CB-Sgo2 was only able to recruit B56a (Figure 2h-k).\" This statement is puzzling. Figure 2J shows hardly any YFP-B56g localization. Why is the localization so different compared to Figure 1 and how was the quantification based on such IF images performed? Importantly, it should be clarified whether this figure and the related Figure 2---figure supplement 1 are carried out under conditions of depletion of Sgo1 and/or Sgo2, as this does not seem to be stated anywhere.

Subsection "Sgo2 provides specificity for centromeric B56 recruitment": \"...CB-Sgo1 was able to localize both B56a and B56g to the inner kinetochore (Figure 2---figure supplement 1).\" This statement is not supported by the data. Under wt conditions, B56g already colocalizes with CENP-C as shown in Figure 1A and 1B. Why are the quantifications (Figure 2K and Figure 2---figure supplement 1D) so different for control conditions?

And given that B56g colocalizes with CENP-C under wt conditions, how do the authors come to the conclusion that CB-Sgo1 recruits B56g to inner kts?

5\) Along the same line, B56a shows a stronger co-localization with CENP-C under control conditions than B56g (compare Figure 2---figure supplement 1B to Figure 2---figure supplement 1D).

The figure legend of Figure 2---figure supplement 1 (CB-Sgo1 recruits both B56a and B56g to centromeres) may be wrong. Apparently, what is meant is.....to inner Kts.

Figure 3---figure supplement 2: There is hardly any signal for wt B56g (Figure 3---figure supplement 2A) that colocalizes with CENP-C. Could the authors please comment on this?

One of the reviewers raised a concern that the data are presented in a very compact manner that may not be readily accessible to a broad readership. While no specific suggestion was provided, the authors should consider this point and consider changes that will improve readability and raise the paper\'s general interest.

10.7554/eLife.42619.026

Author response

*A point emerged strongly in the post-review discussion, namely that quantitative evidence corroborating claims on the role of the newly identified sequence motifs would not simply be nice to have but would strongly reinforce the paper. An analysis* in vitro *with purified B56a and B56g and peptides containing the relevant sequence motifs should aim to assess whether Sgo2 reduces the binding of B56a to BubR1, whether Sgo1 binds directly to Bubr1-B56, and whether these interactions are affected by mutation of the EPVA or TKHG motifs. Based on a significant body of previous work, we believe that these experiments are feasible and can be carried out in a time compatible with an eLife revision.*

We thank the reviewers and editors for their very careful review and valuable comments/suggestions. In general, we agreed that all of the proposed changes would add value to the manuscript. However, as discussed in a subsequent email exchange with the editor, we also believe that the suggestion to use purified components could not be achieved in a timeframe that is compatible with an *eLife* review. This decision was reached for the following reasons:

The proposed work would require the purification of 7 different components (BubR1, B56α, B56γ, PPP2CA, PPP2R1A, Sgo1 and Sgo2) followed by the phosphorylation of one of these components (BubR1) with two kinases (Plk1/Cdk1) in an attempt to generate two stable complexes: (1) Sgo1:pBubR1:PP2A-B56γ, and (2) Sgo2:PP2A-B56α. This second complex could then be tested for its ability to bind to phospho-BubR1. These in vitro assemblies would also then need to be carried out in the presence of peptides against our identified motif to see if complex assembly was prevented. In addition to the obvious time constraints, we were concerned that assembling phospho-dependent interactions in the presence of a purified phosphatase may be difficult, and we would also have no indication as to whether the peptides could adopt a conformation that binds to Sgo1 or Sgo2 with sufficient strength to prevent the key interactions.

Nevertheless, although these in vitro experiments did not seem feasible to us, we did still clearly see the value of trying to address the main questions set out in the review. Therefore, as discussed in our previous email exchange, we have attempted to address these key questions (paraphrased below for clarity) by alternative means:

1\) Does Sgo2 inhibit the ability of B56α to bind to BubR1?

2\) Does Sgo1 bind directly to the BubR1-B56 complex?

3\) Are any effects identified in 1 or 2 dependent on the EPVA/TKHG motif?

4\) Can centromeric cohesion be maintained by only B56α, and not B56γ, as our localisation data would predict.

Below is a summary of the new data that is now included in the manuscript to address these key questions:

1\) Does Sgo2 inhibit the ability of B56a to bind to BubR1?

We have now examined the effect of Sgo2 depletion on the ability of B56α to bind to BubR1 and other LxxIxE-containing proteins. This new data (now included as Figure 6---figure supplement 2) shows that efficient Sgo2 depletion does not enhance the ability of B56α to bind to either BubR1 or other proteins with an LxxIxE motif. Furthermore, we are unable to detect clear Sgo2 signal in any B56 IPs, even though LxxIxE interactions are clearly different between B56α and B56γ. We now have four independent pieces of data to suggest that Sgo2 does not inhibit B56α binding to BubR1. We copy a paragraph from the new Discussion section that expands on this point:

"...a simple explanation could be that Sgo2 interaction obscures the LxxIxE binding pocket. However, this appears unlikely for four reasons: (1) Sgo2 depletion does not relocalise B56α to kinetochores (Figure 2A,B), (2) Sgo2 depletion does not enhance the ability of B56α to bind to BubR1 or other LxxIxE motifs during mitosis (Figure 6---figure supplement 2), (3) centromere and kinetochore binding can occur together in certain B56α-γ chimaeras (Figure 6---figure supplement 1B), and (4) the regions that define each of these localisations do not fully overlap (Figure 6G). Although we believe these results suggest that Sgo2 is unlikely to block LxxIxE interaction, in vitro experiments with purified components would ultimately be needed to formally rule this out."

2\) Does Sgo1 bind directly to the BubR1-B56 complex?

Current structural data suggests that Sgo1 and B56 could interact simultaneously with BubR1, and our data indicates that a BubR1-B56-Sgo1 complex could potentially exist at kinetochores. Considering that Sgo1 binds directly to the PP2A-B56 complex, we reasoned that we could address this question by immunoprecipitating BubR1-wt or -dKARD (which cannot bind B56). If Sgo1 is detected in BubR1-wt, but not BubR1-dKARD IPs, then this would suggest that BubR1 requires B56 for Sgo1 interaction; thus, implying the existence of a BubR1-PP2A-B56:Sgo1 complex.

We therefore immunoprecipitated BubR1-wt or dKARD from nocodazole-arrested cells and probed for Sgo1 and B56. The figure below shows that we could detect B56γ, but not B56α, in immunoprecipates from only BubR1-wt cells, as predicted. Unfortunately, however, we were unable to detect Sgo1 in any of these IPs, even after scaling up the input and performing rapid purifications (with a GFP-nanobody) to try to detect transient interactions. Therefore, we cannot currently state whether Sgo1 does not form a complex with BubR1-B56 in cells, or whether this complex is simply not stable enough to be detected following immunoprecipitation. We suggest to keep this as "results not shown" and have added the following new paragraph to the discussion:

"We were unable to detect Sgo1 in YFP-BubR1 immunoprecipitates (results not shown), however, this could simply reflect an interaction that is either transient or unstable away from kinetochores. It will be important in future to clarify exactly how Sgo1 collaborates with BubR1 to control B56 localisation and, in particular, to determine whether Sgo1 can interact with BubR1:PP2A-B56 complexes directly."

![](elife-42619-resp-fig1){#respfig1}

We would like to stress that we do not see this question as critical to our study at all. It follows on from a novel observation that we made regarding kinetochore B56 recruitment, but this does not impact on isoform-specific localisation at all (Sgo1 binds all B56 isoforms equally well: see Figure 2---figure supplement 1). That is why we believe this question is suitable to be left as a future direction.

3\) Are any effects identified in 1 or 2 dependent on the EPVA/TKHG motif?

As outlined in point 1 above, Sgo2 is very unlikely to affect LxxIxE/BubR1 binding. Therefore, although the EPVA motif is definitely required for Sgo2 binding (Figure 6A-D), this is unlikely to impact on LxxIxE binding. In addition, we believe that the EPVA/TKHG motif cannot strongly influence Sgo1 binding because Sgo1 can bind to both B56α and B56g (Figure 2---figure supplement 1).

4\) Can centromeric cohesion be maintained by only B56α, and not B56γ, as our localisation data predicts.

We were actually very surprised that this was not considered an essential revision, given than it is not possible to formally demonstrate a true division of labour between B56 isoforms -- as our title states -- without this information. Furthermore, in our opinion, this was perhaps the most novel aspect of our study given that there are no previous demonstration that B56 isoforms can control separate cellular processes. This particular advance was not commented on in the summary by the reviewers, which we suspect is the main reason that this point was not seen as essential.

Nevertheless, we now include this important new data in Figure 1c, which demonstrates that, as predicted previously, depletion of all B56 isoforms leads to premature sister chromatid splitting, and this can be fully rescued if B56α is retained, but not if only B56γ remains.

Other important points:

> For some intensity plots, the authors indicate if the observed differences are significant or not (Figure 2, Figure 3B and D, Figure 2---figure supplement 1, Figure 3---figure supplement 2, Figure 6) but for others they do not (Figure 3H and J, Figure 3---figure supplement 1). Please add this information to all the plots.

Thank you for pointing out this omission. The correct stats have now been added to all the Figures.

> In some of the presented images, a clear-cut centromeric or kinetochore localization of B5a and B56g, respectively, as compared to the marker proteins Sgo2 and CENP-C, was not immediately recognisable (see for example Figure 1B). This is particularly true for endogenously tagged B56g, which is almost equally abundant at kinetochores and centromeres (see Figure 1---figure supplement 3D). At the very least, the partially overlapping localisation should be acknowledged.

We agree that it is not possible to stringently categorise localisation based on the results presented. The text has now been modified to make careful statements such as predominantly or mainly centromeric/kinetochore.

> Kinetochore associated B56g, but not centromeric B56a, was sufficient to maintain the kinetochore functions of PP2A-B56 after the knockdown of all other B56 isoforms. The authors should explicitly state here that this cannot be explained by a lower expression level of B56a in these cells, as is only shown later in Figure 4A (but never commented upon).

A statement has been added to the text to explain that B56α and B56γ are both consistently expressed in HeLa cells (in relation to Figure 1---figure supplement 2 and Figure 1---figure supplement 3). Furthermore, the new data indicates that preserving B56α can only retain centromeric functions, whereas retaining B56γ only preserves kinetochore functions. This removes any concerns that the observed effects might be due to low level expression of one particular isoform.

> The reverse experiment, addressing whether B56a alone, but not B56g, can maintain the centromeric functions of PP2A-B56 is lacking and the authors could elect to carry it out.

Indeed, we agree that this was a very important omission given that the title of the manuscript refers to shared labours between B56 isoforms at the kinetochore and centromere. New data has now been included to demonstrate that B56γ cannot support centromeric cohesion, whereas B56a can (Figure 1C).

> The relative kinetochore intensity (e.g. Figure 1---figure supplement 5C) apparently refers to the combined kinetochore + centromere targeting. The normalised kinetochore intensity then shows the distribution between kinetochores and centromeres (e.g. Figure 1---figure supplement 5D). The y-axes should be re-defined to make this difference clear.

The axes and graph titles have now been changed to clarify this point.

> Figure 1---figure supplement 2. Please include the WB for the other B56 isoforms.

A new western has now been inserted to include all B56 isoforms, except for B56β which was undetectable.

> In Figure 2 and Figure 2---figure supplement 1, the authors aim to demonstrate that specific binding of B56a to Sgo2 contributes to its centromeric localization. With these figures, the following problems were identified:
>
> Figure 2C: Upon Sgo1 depletion, B56a seems to change its localization from a primarily centromeric localization to a primarily kt localization. Yet, this is not reflected in the quantifications shown in 2D and 2E.

The graph in Figure 2D shows relative intensity of centromere and kinetochore staining combined, which is why this does not change following Sgo1 depletion (B56a simply redistributes from centromere to kinetochore under this condition). The previous axis indicated "kinetochore intensities", which was incorrect since the centromere/kinetochore cannot be distinguished with this type of analysis. All of these axes have therefore now been changed to read "Cen/Kt intensity" to avoid confusion.

The lineplots in Figure 2E allows the Cen/Kt can be visualised separately, and this demonstrates that B56a redistributes towards the kinetochore under this condition: the new Figure 2E now contains additional repeats to reduce variability and this does indeed demonstrate redistribution towards the kinetochore.

> Furthermore, Figure 2D gives the impression that Sgo1 is very efficiently depleted in Sgo1RNAi cells. The IF image shown in C gives a different impression. Could the authors please comment on this?

We try to always choose images that most closely represent the mean data (a statement is included in the methods to indicates this). In the previous Figure 2D the punctate staining was actually background staining that do not consistently align with kinetochores and can also be seen in the siCon image. However, the punctate pattern visible in the zoom was indeed confusing since it did partially overlap with kinetochore. Therefore, a different region has now been selected to avoid confusion and to better represent the minimal kinetochore staining seen under this condition.

> Subsection "Sgo2 provides specificity for centromeric B56 recruitment": \"..., CB-Sgo2 was only able to recruit B56a (Figure 2h-k).\" This statement is puzzling. Figure 2J shows hardly any YFP-B56g localization. Why is the localization so different compared to Figure 1 and how was the quantification based on such IF images performed?

Thank you for pointing out this error. This image was not representative of the data because it had high background cytosolic levels and poor kinetochore staining. A new example image has now been included that better represents the mean data.

> Importantly, it should be clarified whether this figure and the related Figure 2---figure supplement 1 are carried out under conditions of depletion of Sgo1 and/or Sgo2, as this does not seem to be stated anywhere.

The CB-Sgo1/2 experiments were all performed in the presence of endogenous Sgo1/2. This has now been clarified in the Materials and methods section.

> Subsection "Sgo2 provides specificity for centromeric B56 recruitment": \"...CB-Sgo1 was able to localize both B56a and B56g to the inner kinetochore (Figure 2---figure supplement 1).\" This statement is not supported by the data. Under wt conditions, B56g already colocalizes with CENP-C as shown in Figure 1A and 1B. Why are the quantifications (Figure 2K and Figure 2---figure supplement 1D) so different for control conditions?
>
> And given that B56g colocalizes with CENP-C under wt conditions, how do the authors come to the conclusion that CB-Sgo1 recruits B56g to inner kts?

Regarding points 3 and 4:

Under wt conditions, B56a and B56g already colocalise with the centromere or kinetochore, respectively (Figure 1A and B). The later figures with CB-Sgo1/2 (Figures2k, S6d etc.) still contain this baseline Cen/Kt localisation, but we then quantify the additional localisation induced by CB-Sgo1/2 expression. The same strategy was previously used by Meppelink et al., 2015 to show recruitment of B56d to CB-Sgo1. Our data indicate that CB-Sgo2 increases B56a (Figure 2I), but not B56g (Figure 2K), whereas CB-Sgo1 causes a large increase in both B56a and B56g at the Cen/Kt (Figure 2---figure supplement 1). Therefore, although the background Cen/Kt does complicate the overall interpretation (this is now clarified in the text), we still believe that our previous statements were supported by the data; given that we observe statistically significant increases only in certain conditions (i.e. in all CB-Sgo1 or -2 conditions, except for CB-Sgo2 + B56g). Please note, that we chose to use the inner kinetochore for these experiments in spite of these difficulties, because it may be important given that Aurora B activity was previously reported to be required for Sgo2:B56 interaction (Tanno et al., 2010).

> Along the same line, B56a shows a stronger co-localization with CENP-C under control conditions than B56g (compare Figure 2---figure supplement 1B to Figure 2---figure supplement 1D).

Thank you for pointing this out. The image in S6D did not demonstrate the clear kt localisation in B56g controls. This image has now been changed for a more representative alternative (now Figure 2---figure supplement 1B and D).

> The figure legend of Figure 2---figure supplement 1 (CB-Sgo1 recruits both B56a and B56g to centromeres) may be wrong. Apparently, what is meant is.....to inner Kts.

As stated above, we have now correctly labelled all these axes to indicate "Cen/KT intensities" since we cannot distinguish between these two localisations in this type of analysis.

> Figure 3---figure supplement 2: There is hardly any signal for wt B56g (Figure 3---figure supplement 2A) that colocalizes with CENP-C. Could the authors please comment on this?

The cells imaged in Figure 3---figure supplement 2A are in interphase. Although B56γ is present in the nucleus in interphase, its main kinetochore receptor, BubR1, is not.: BUBR1 is only recruited to the kinetochore following nuclear envelope breakdown (see Nijenhuis et al., 2014). As such, in the wt situation prior to NEB, B56γ does not colocalize with CENP-C at kinetochores.

> One of the reviewers raised a concern that the data are presented in a very compact manner that may not be readily accessible to a broad readership. While no specific suggestion was provided, the authors should consider this point and consider changes that will improve readability and raise the paper\'s general interest.

We thank the reviewer for this comment. We have now expanded the text slightly in key areas to explain things better to readers who do not have experience in kinetochore signalling. Hopefully this will now help to raise interest from a general audience.
